Innovative therapies to treat and cure
hepatitis B virus (HBV) and other viral diseases

The only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in Development

Combining the ASPIN, ATI-2173, with a Nucleoside Analogue (NA), such as Tenofovir (TDF) or Entecavir (ETV), in a one-pill, once-a-day regimen could completely shut down HBV polymerase activity and viral replication, potentially curing HBV infected individuals

ATI-2173
Active Site Polymerase Inhibitor Nucleotide
ATI-2173
HBV
Hepatitis B virus affects 290 million + worldwide
HBV
HDV
Hepatitis delta virus co-infects 5-6% of HBV-infected persons
HDV

News

June 11, 2021
Antios Therapeutics Announces Poster Presentation at the Inaugural HBV-TAG Conference
April 27, 2021
Antios Therapeutics Continues Building Experienced Executive Team with Appointments of Katie Laessig, M.D., as SVP, Global Regulatory Affairs and Karen Fusaro as SVP, Clinical Operations
April 21, 2021
Antios Therapeutics Doses First Patients in SAVE 1, a Phase 2a Study of ATI-2173 in Patients with Chronic Hepatitis B Virus (HBV)
SEE ALL NEWS

EASL presentations:

Pharmacokinetics of ATI-2173, a novel active site polymerase inhibitor nucleoside, in a Phase 1b clinical trial
–
Phase 1 Results for ATI-2173, a novel active site polymerase inhibitor nucleotide, in HBV-infected subjects

Improving lives through the
treatment of viral diseases